Phase 3 biotech developing a nasal spray formulation for dry eye disease.
Industry: Health Care
First Day Return: +17.4%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 10/04/2019 |
Offer Price | $16.00 |
Price Range $16.00 - $18.00 | |
Offer Shares (mm) | 5.0 |
Deal Size ($mm) | $80 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 10/30/2019 |
Offer Price | IPO Intelligence Only |
Price Range | IPO Intelligence Only |
Offer Shares (mm) | IPO Intelligence Only |
Deal Size ($mm) | $80 |
Lock-Up Date | IPO Intelligence Only |
Street Research | IPO Intelligence Only |
Underwriters |
---|
IPO Intelligence Only |
Company Data | |
---|---|
Headquarters | Princeton, NJ, United States |
Founded | 2015 |
Employees at IPO | 18 |
Website www.oysterpointrx.com |